Evidence map›Paper›PMID 30259272›Full record

ArticleHead and neck pathology2019

MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene.

Veronica Balatti, Steve Oghumu, Arianna Bottoni, Kati Maharry, Luciano Cascione, Paolo Fadda, Anil Parwani, Carlo Croce, O Hans Iwenofu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head and neck pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. miRNAs in Cancer (Review of Literature).International journal of molecular sciences · 2022
    Review
  3. The emerging role of miR-10 family in gastric cancer.Cell cycle (Georgetown, Tex.) · 2021
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Veronica BalattiDepartment of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, USA.
Steve OghumuDepartment of Pathology and Laboratory Medicine, The Ohio State University, Columbus, USA.
Arianna BottoniDepartment of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, USA.
Kati MaharryDepartment of Epidemiology, College of Public Health, The Ohio State University, Columbus, USA.
Luciano CascioneDepartment of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, USA.
Paolo FaddaDepartment of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, USA.
Anil ParwaniDepartment of Pathology and Laboratory Medicine, The Ohio State University, Columbus, USA.
Carlo CroceDepartment of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, USA.
O Hans IwenofuDepartment of Pathology and Laboratory Medicine, The Ohio State University, Columbus, USA. Hans.Iwenofu@osumc.edu.
The Ohio State University · USInstitute of Oncology Research · CH

Funding

Mechanisms of Oral Cancer Inhibition by Bioactive Phytochemicals in Black RaspberriesK01CA207599 · NCI · OHIO STATE UNIVERSITY · PI OGHUMU, STEVE ONYEKA · 2017 to 2021
$715k
National Cancer Institute K01 CA207599NCI NIH HHS K01 CA207599
6 · The paper itself

Abstract

Salivary duct carcinomas (SDC) and Her2/Neu3-overexpressing invasive breast carcinomas (HNPIBC/IBC) are histologically indistinguishable. We investigated whether common histopathologic and immunophenotypic features of SDC and IBC are mirrored by a similar microRNA (miRNA) profile. MiRNA profiling of 5 SDCs, 6 IBCs Her2/Neu3+, and 5 high-grade ductal breast carcinoma in situ (DCIS) was performed by NanoString platform. Selected miRNAs and HOXA1 gene were validated by RT-PCR. We observed similar miRNA expression profiles between IBC and SDC with the exception of 2 miRNAs, miR-10a and miR-142-3p, which were higher in IBC tumors. DCIS tumors displayed increased expression of miR-10a, miR-99a, miR-331-3p and miR-335, and decreased expression of miR-15a, miR-16 and miR-19b compared to SDC. The normal salivary gland and breast tissues also showed similar expression profiles. Interestingly, miR-10a was selectively increased in both IBC and normal breast tissue compared to SDC and normal salivary gland tissue. Moreover, our NanoString and RT-PCR data confirmed that miR-10a was upregulated in IBC and DCIS compared to SDC. Finally, we show downregulation of HOXA1, a miR-10 target, in IBC tumors compared to normal breast tissue. Taken together, our data demonstrates that, based on miRNA profiling, SDC is closely related to HNPIBC. Our results also suggest that miR-10a is differentially expressed in IBC compared to SDC and may have potential utility as a diagnostic biomarker in synchronous or metachronous malignant epithelial malignancies involving both organs. In addition, miR-10a could be playing an important role as a mammary-specific oncogene, involved in breast cancer initiation (DCIS) and progression (IBC), through mechanisms that include modulation of HOXA1 gene expression.

Indexed as

Breast NeoplasmsCarcinoma, DuctalErb-b2 Receptor Tyrosine KinasesFemaleGene Expression ProfilingHumansMicroRNAsSalivary Gland NeoplasmsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMicroRNAsMIRN10 microRNA, humanHer2/Neu+ breast carcinomaMicroRNA profilingMiRNA-10OncogeneSalivary duct carcinoma

Identifiers

PMID30259272
PMCPMC6684709
OpenAlexW2894179290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.